Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05321277 · ClinicalTrials.gov registry record · NA

Response of Cardiometabolic Biomarkers and Gut Microbiota to Walnut Consumption

A NA study of Cardiovascular Diseases, sponsored by University of California, Davis.

Active
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05321277: Active NA study of Cardiovascular Diseases, sponsored by University of California, Davis.

NCT05321277 is a NA study of Cardiovascular Diseases that is active but no longer recruiting, run by University of California, Davis. The registered enrollment target is 30 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05321277, a NA study of Cardiovascular Diseases, is active but no longer recruiting, sponsored by University of California, Davis.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to test if eating walnuts will cause any changes in blood lipids (like good and bad cholesterol, for example) and levels of inflammation in the blood, as well as changes in the bacteria living in the gut.

Primary Outcome

Measure for changes in the levels of HDL and LDL in separated plasma; measured in units of mg/dL. Blood will be assessed for the fasting (baseline) sample at each of the 4 study visits.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Walnuts
  • DIETARY_SUPPLEMENT No-nut diet

Study Locations (1)

California

  • Ragle Human Nutrition Center - Davis

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-04-19
Est. Completion 2026-08
Phase NA
University of California, Davis

657 total trials

What the registry record for NCT05321277 still lists

NCT05321277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Walnuts is the first listed.

NCT05321277 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05321277 about?

NCT05321277 is a clinical study titled "Response of Cardiometabolic Biomarkers and Gut Microbiota to Walnut Consumption". The purpose of this research is to test if eating walnuts will cause any changes in blood lipids (like good and bad cholesterol, for example) and levels of inflammation in the blood, as well as changes in the bacteria living in the gut.

What is the current status of trial NCT05321277?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-04-19. Estimated completion is 2026-08.

What conditions does trial NCT05321277 study?

This clinical trial studies the following conditions: Cardiovascular Diseases.

What interventions are being tested in trial NCT05321277?

The interventions under investigation include: Walnuts (DIETARY_SUPPLEMENT), No-nut diet (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05321277?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05321277 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05321277's enrollment target sits among peer trials

30 262nd of 300 higher than 33 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05321277, the US trial registry maintained by the National Library of Medicine. NCT05321277 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.